New strategy for diabetes treatment: Newly-discovered compound slows natural degradation of insulin in the body

May 21, 2014
Blood glucose monitoring. Credit: Wikipedia

With the discovery of a compound that can slow the degradation of insulin in animals, scientists at Harvard have opened the door to a potential new treatment for diabetes.

The new approach, described by Professor of Chemistry and Chemical Biology David Liu and Associate Professor of Chemistry and Chemical Biology Alan Saghatelian, uses a newly discovered compound to inhibit degrading enzyme (IDE). Inhibiting IDE in mice, they show, elevates and promotes insulin signaling in vivo. Eventually, the use of this compound in patients may help maintain higher insulin levels to improve and therefore to treat diabetes. The discovery of the new compound, and tests demonstrating its efficacy in mice, are outlined in an May 21 paper in Nature.

"This work validates a new potential target for the treatment of diabetes," Liu said. "What we show is that inhibiting IDE in an animal can improve glucose tolerance under conditions that mimic the intake of a meal if you administer this compound beforehand."

For decades, researchers said, insulin-based diabetes treatments consisted of three main strategies – inject insulin into diabetics, provide drugs that stimulate , or administer drugs that make the body more sensitive to insulin.

"What's been missing has been the ability to regulate the degradation of insulin," Saghatelian said. "The technological leap we've made was in identifying a molecule that allows that to happen. This opens up a new avenue to control insulin signaling in vivo."

To identify the new molecule, Liu, Saghatelian, and their co-workers turned to DNA-templated synthesis, a method for creating new molecules that self-assemble according to an attached DNA sequence.

The system works by combining DNA "templates" –short segments of DNA – with the chemical building blocks of molecules, each of which is linked to its own complementary piece of DNA. As the DNA segments bind together, the building blocks are brought together and react with one another, forming more complex molecules. The composition of the resulting molecules can be identified by sequencing their associated DNA strands.

"We took a library of about 14,000 DNA templates, and combined it with several sets of DNA-linked reagents," Liu said. "The resulting synthesis of about 14,000 small molecules was largely driven by, and programmed by, DNA base pairing. At the end of that process, we had 14,000 strands of DNA, each with a unique compound at its end."

Researchers then took that library of DNA-linked , and incubated it with IDE in the hopes that some might bind to the enzyme.

"Our hypothesis was that the molecules that were retained by IDE might modulate IDE's activity," Liu said. "In this case, right out of the library, we found quite a potent and selective inhibitor. Perhaps most important, this molecular had a good half-life in animals, so it could be used to answer the 60-year-old question of what happens when you slow down the natural degradation of insulin in the body."

Identifying a molecule that could inhibit IDE, however, was only the first step.

Researchers were also able to show that the new compound remained active in the body, and experiments with mice showed that it was able to help regulate blood sugar levels.

"To validate that this strategy – of slowing the degradation of insulin – is actually therapeutically useful, we have to show that this compound can transiently inhibit the target, and show that it has a benefit in animals," Liu said. "That is what we demonstrate in this study."

In addition to pointing the way toward a new way to treat diabetes, researchers uncovered new information about how IDE works in the body.

"In the process of resolving some seemingly paradoxical results, we discovered that IDE is actually somewhat misnamed," he said. "It doesn't just degrade insulin, it degrades at least two other important glucose-regulating peptide hormones – glucagon and amylin."

While the discovery of the new molecule is exciting, Liu emphasized that it may still be some time before the new compound finds its way onto pharmacy shelves.

"To develop a drug requires a number of additional tests and developments," he said. "But this work validates IDE as a new target for the treatment of diabetes, and it provides experimental tools that can be used to develop this compound further into potential therapeutic leads."

"What this paper has done is given a proof of concept that targeting this protein is the way to go," Saghatelian said. "To make the leap from this molecule to a drug, there are other factors that need to be optimized, but we've hung the carrot out there for the pharmaceutical industry and other labs to start looking at IDE as a potential target for treating diabetes, and to push through the remaining obstacles that are there. We've shown it's worth the effort to look into this more deeply, and hopefully what we've done is opened people's eyes to IDE as a valid therapeutic target."

Explore further: Research team tests alternative approach to treating diabetes

More information: Paper: dx.doi.org/10.1038/nature13297

Related Stories

Research team tests alternative approach to treating diabetes

June 9, 2011
In a mouse study, scientists at Mayo Clinic Florida have demonstrated the feasibility of a promising new strategy for treating human type 2 diabetes, which affects more than 200 million people worldwide.

Intensive insulin provides survival

May 13, 2014
Long-term follow-up of the DIGAMI 1 trial – a landmark study of type 2 diabetes in Sweden – shows that intensive insulin treatment prolonged life by more than 2 years in patients with diabetes after a heart attack, compared ...

Scientists discover a natural molecule to treat type 2 diabetes

May 12, 2014
Researchers at the Université Laval Faculty of Medicine, the Quebec Heart and Lung Institute Research Center, and the Institute of Nutrition and Functional Foods have discovered a natural molecule that could be used to treat ...

Newly discovered human peptide may become a new treatment for diabetes

December 2, 2013
Even if the obesity trend cannot be reversed, here's hope that it's partner in crime—diabetes—might be thwarted. New research published in the December 2013 issue of The FASEB Journal shows how a recently discovered human ...

Loss of function of a single gene linked to diabetes in mice

January 4, 2014
Researchers from the University of Illinois at Chicago College of Medicine have found that dysfunction in a single gene in mice causes fasting hyperglycemia, one of the major symptoms of type 2 diabetes. Their findings were ...

Recommended for you

Scientists discover a new way to treat type 2 diabetes

July 21, 2017
Medication currently being used to treat obesity is also proving to have significant health benefits for patients with type 2 diabetes. A new study published today in Molecular Metabolism explains how this therapeutic benefit ...

Alzheimer's drug cuts hallmark inflammation related to metabolic syndrome by 25 percent

July 20, 2017
An existing Alzheimer's medication slashes inflammation and insulin resistance in patients with metabolic syndrome, a potential therapeutic intervention for a highly dangerous condition affecting 30 percent of adults in the ...

Diabetes or its precursor affects 100 million Americans

July 19, 2017
Almost one-third of the US population—100 million people—either has diabetes or its precursor condition, known as pre-diabetes, said a government report Tuesday.

One virus may protect against type 1 diabetes, others may increase risk

July 11, 2017
Doctors can't predict who will develop type 1 diabetes, a chronic autoimmune disease in which the immune system destroys the cells needed to control blood-sugar levels, requiring daily insulin injections and continual monitoring.

Diabetes complications are a risk factor for repeat hospitalizations, study shows

July 7, 2017
For patients with diabetes, one reason for hospitalization and unplanned hospital readmission is severe dysglycemia (uncontrolled hyperglycemia - high blood sugar, or hypoglycemia - low blood sugar), says new research published ...

Researchers identify promising target to protect bone in patients with diabetes

July 7, 2017
Utilizing metabolomics research techniques, NYU Dentistry researchers investigated the underlying biochemical activity and signaling within the bone marrow of hyperglycemic mice with hopes of reducing fracture risks of diabetics

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.